Liver Diseases Therapeutics Market, Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmaci

Liver Diseases Therapeutics Market, Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Liver Diseases Therapeutics are used for treatment of hepatitis A, hepatitis B, and hepatitis C; liver fibrosis, liver cancer; fatty liver disease and cirrhosis; hemochromatosis and Wilson disease. Increasing prevalence of liver diseases such as liver fibrosis is expected to propel growth of the global liver diseases therapeutics market over the forecast period. Other factors influencing the growth of the market constitute of growing prevalence of risk factors such as chronic infection with hepatitis B or C virus, compromised immune system due to co-infection with HIV or use of immunosuppressive drugs after a liver transplant.
Furthermore, Increasing R&D of novel therapeutics for treatment of liver diseases is expected to offer lucrative growth opportunities for players in the global liver diseases therapeutics market
Key features of the study:
This report provides in-depth analysis of the Liver Diseases Therapeutics market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global Liver Diseases Therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global Liver Diseases Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Liver Diseases Therapeutics market
Detailed Segmentation:
Liver Diseases Therapeutics Market, Therapy Type:
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
Liver Diseases Therapeutics Market, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Liver Diseases Therapeutics Market, By Region:
North America
Therapy Type:
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
Therapy Type:
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Therapy Type:
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Therapy Type:
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Therapy Type:
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
Therapy Type:
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Astellas Pharma Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Bristol-Myers Squibb
Gilead Sciences
Glaxosmithkline Plc
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Novartis AG
Sanofi S.A
Pfizer Inc.
Takeda Pharmaceutical
Valeant Pharmaceuticals
Watson Pharmaceuticals, Inc.
Theratechnologies Inc.
Alnylam Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc.
Dicerna Pharmaceuticals, Inc.
Endo International
Provectus Biopharmaceuticals Inc.
MAX BioPharma, Inc.
“*” marked represents similar segmentation in other categories in the respective section.